2031-17: So Many Atypical Antipsychotics How to Choose: The Current Psychopharmacological Treatment Landscape for Psychotic Spectrum Disorders

The advent of AA’s in 1989,  to the latest 2015 approval, offers clinicians many choices when treating psychotic spectrum disorders. The selection, dose titration, and cross taper of these medications is challenging. Selecting and stabilizing a patient with a psychotic disorder requires vast knowledge and experience using various AA’s.

Presenter:  Dawn Vanderhoef, PhD, DNP, PMHNP-BC, FAANP

Disclosures:  The presenter and planners have no conflict of interest or commercial support to disclose.  Off-label uses will be discussed during this presentation.

Session Length:  44 minutes

Target Audience:  RN, APRN

Learning Outcomes:
Upon completion of this presentation, the participant will be able to:

1. Describe the diagnostic criteria for psychotic spectrum disorders.
2. Compare and contrast the psychopharmacologic properties of Atypical Antipsychotics (AA’s).
3. Appraise the evidence for Atypical Antipsychotic use in persons with a psychotic disorder.

Keywords:  Atypical Antipsychotics, Psychosis 

Continuing Nursing Education:
0.75 pharmacology contact hours.  * In order to receive contact hours, you must: Listen to presentation, complete an evaluation, and earn a passing score on the post-test before the expiration date. You will have 5 tries to correctly answer the questions on the post-test and a score of 80% is required to pass. Once you have passed and completed an evaluation, the certificate will be generated online, available for you to print immediately. You cannot earn credit unless all steps are completed.

The American Psychiatric Nurses Association is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

Originally Presented
APNA 31st Annual Conference
Phoenix, Arizona
Thursday, October 19, 2017
12:15pm - 1:00pm

The contact hours for this session expire:  January 1, 2021